Official facilitator of


Durvalumab effective in lung cancer

12 September 2019 17:19

Adding an immunotherapeutic drug durvalumaba to chemotherapy improves overall survival in patients with small cell lung cancer patients at advanced stage. This was reported by researchers at the World Conference on Lung Cancer IASLC 2019 organized by the International Association for the Study of Lung Cancer.

For information on how to carry out the treatment of lung cancer in Israel, the best specialists of the country, leave a request and we will contact you shortly.

The study was presented by Dr. Luis Paz-Ares from the hospital of the University Universidad Complutense and Ciberonc.

Small cell lung cancer at advanced stage is defined as the stage at which a cancer spreads to other parts of the body such as the liver and brain. The average survival time after diagnosis is 10 months.

In the study, researchers randomly assigned 537 patients with metastatic lung cancer who have not previously been treated. Participants received either 4 durvalumab plus chemotherapy etoposide-platinum (EP), or durvalumab plus tremelimumab plus EP 4-year or up to 6 courses only EP. The data presented at the conference concerned only durvalumaba group compared with the control group.

The patients in the immunotherapy group reached a median survival of 13 months compared with 10.3 months in the control group FL. And 33.9% of patients receiving durvalumab were alive after 18 months, compared with 24.7% in the control group of the study.

"Adding to EP durvalumaba as first-line treatment of non-small cell lung cancer is at a late stage considerably improved overall survival (reduction in risk of death by 27%) compared with the control group. Moreover, the chemo-immunotherapy mode allows you to select one of the platinum drugs (carboplatin or cisplatin), reflecting current clinical practice to this complex disease, "- added the researchers.



The form Submitting the this by you agree to the privacy policy


No comments yet

new comment


definitely (will not be published)